Dyadic International (DYAI) Expected to Announce Quarterly Earnings on Wednesday

Dyadic International (NASDAQ:DYAI) is expected to post its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Dyadic International to post earnings of ($0.04) per share and revenue of $0.9040 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 5:00 PM ET.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). Dyadic International had a negative return on equity of 695.96% and a negative net margin of 239.67%.The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.34 million. On average, analysts expect Dyadic International to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dyadic International Trading Up 2.5%

Shares of NASDAQ:DYAI opened at $0.77 on Wednesday. The business’s 50-day moving average is $0.82 and its 200 day moving average is $0.90. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.68 and a quick ratio of 2.68. Dyadic International has a 1 year low of $0.65 and a 1 year high of $1.35. The firm has a market capitalization of $28.06 million, a P/E ratio of -3.08 and a beta of 1.18.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dyadic International presently has an average rating of “Hold” and a consensus target price of $3.00.

Hedge Funds Weigh In On Dyadic International

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYAI. Geode Capital Management LLC lifted its position in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares during the period. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the third quarter worth about $190,000. Finally, Bank of America Corp DE raised its stake in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.